Letermovir
- Generic Name
- Letermovir
- Brand Names
- Prevymis
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28F4N4O4
- CAS Number
- 917389-32-3
- Unique Ingredient Identifier
- 1H09Y5WO1F
- Background
Letermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors. Letermovir has recieved both priority and orphan drug status from the FDA. It is cur...
- Indication
Letermovir is indicated for prophylaxis against cytomegalovirus (CMV) infection and disease in adult recipients of an allogeneic hematopoietic stem cell transplant (HSCT) who are CMV-seropositive. It is also indicated for prophylaxis against CMV disease in adult kidney transplant recipients who are at risk (i.e. donor CMV-seropositive/recipient CMV-seronegat...
- Associated Conditions
- Cytomegalovirus (CMV) Infections
- Associated Therapies
- -
Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China
- Conditions
- Interventions
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2024-04-30
- Target Recruit Count
- 200
- Registration Number
- NCT05789615
- Locations
- 🇨🇳
The First Affiliated Hospital of Soochow university, Suzhou, Jiangsu, China
A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of CMV Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)
- First Posted Date
- 2023-03-10
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT05763823
- Locations
- 🇨🇳
Institute of hematology&blood disease hospital-Hematology ( Site 0030), Tianjin, Tianjin, China
🇨🇳Shenzhen Second People's Hospital-Hematology Department ( Site 0006), Shenzhen, Guangdong, China
🇨🇳The First Affiliated Hospital of Soochow University-hematology department ( Site 0029), Suzhou, Jiangsu, China
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 143
- Registration Number
- NCT05711667
- Locations
- 🇺🇸
UCSF Medical Center-Mission Bay, San Francisco, California, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
- Conditions
- Interventions
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05656599
- Locations
- 🇨🇳
Department of Hematology, Peking University People's Hospital, Beijing, Beijing, China
🇨🇳People's Hospital of Peking University, Beijing, China
Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2022-11-23
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT05626530
- Locations
- 🇺🇸
Tufts Medical Center-Division of Geographic Medicine and Infectious Diseases, Boston, Massachusetts, United States
Letermovir in ART-treated HIV-infected Persons
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Jean-Pierre Routy
- Target Recruit Count
- 60
- Registration Number
- NCT05362916
- Locations
- 🇨🇦
Mcgill University Health Center, Montreal, Quebec, Canada
Letermovir for CMV Prevention After Lung Transplantation
- Conditions
- Interventions
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Fernanda P Silveira, MD, MS
- Target Recruit Count
- 16
- Registration Number
- NCT05041426
- Locations
- 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States
Letermovir Use in Heart Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2021-05-27
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Tufts Medical Center
- Target Recruit Count
- 31
- Registration Number
- NCT04904614
- Locations
- 🇺🇸
Tufts Medical Center, Boston, Massachusetts, United States
Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - STEP 1 (CYMEVAL3-STEP1)
- Conditions
- Interventions
- First Posted Date
- 2021-02-01
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 7
- Registration Number
- NCT04732260
- Locations
- 🇫🇷
Hôpital Necker - Enfants malades, Paris, France
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
- Conditions
- Interventions
- First Posted Date
- 2020-03-18
- Last Posted Date
- 2024-07-18
- Target Recruit Count
- 6
- Registration Number
- NCT04312841
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.